| Full text | |
| Author(s): |
Bacchi, Pedro Starzynski
[1, 2, 3]
;
Bloise, Antonio Carlos
[4]
;
Bustos, Silvina Odete
[1, 2, 3]
;
Zimmermann, Lara
[1, 2, 3]
;
Chammas, Roger
[1, 2, 3]
;
Rabbani, Said Rahnamaye
[4]
Total Authors: 6
|
| Affiliation: | [1] Univ Sao Paulo, Inst Cancer Estado Sao Paulo, Lab Oncol Expt, BR-01246000 Sao Paulo - Brazil
[2] Univ Sao Paulo, Inst Cancer Estado Sao Paulo, Ctr Invest Translac Oncol, BR-01246000 Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med, BR-01246000 Sao Paulo - Brazil
[4] Univ Sao Paulo, Inst Fis, Lab Ressonancia Magnet, BR-05508090 Sao Paulo - Brazil
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | SPRINGERPLUS; v. 3, AUG 26 2014. |
| Web of Science Citations: | 1 |
| Abstract | |
Metabolomics has proven an useful tool for systems biology. Here we have used a metabolomics approach to identify conditions in which de novo expression of an established tumor marker, galectin-3, would confer a potential selective advantage for melanoma growth and survival. A murine melanoma cell line (Tm1) that lacks galectin-3 was modified to express it or not (Tm1.G2 and Tm1.N3, respectively). These variant cell line were then exposed to conditions of controlled oxygen tensions and glucose levels. Metabolic profiling of intracellular metabolites of cells exposed to these conditions was obtained in steady state using high resolution H-1 Magnetic Resonance Spectroscopy (H-1-MRS) and multivariate statistical analysis. The Nuclear Magnetic Resonance (NMR) spectra contained a large number of absorption lines from which we were able to distinguish 20 metabolites, 3 fatty acids and some absorption lines and clusters were not identified. Principal Components Analysis (PCA) allowed for the discrimination of 2 experimental conditions in which expression of the tumor marker galectin-3 may play a significant role, namely exposure of cells to hypoxia under high glucose. Interestingly, under all other experimental conditions tested, the cellular system was quite robust. Our results suggest that the Metabolomics approach can be used to access information about changes in many metabolic pathways induced in tumorigenic cells and to allow the evaluation of their behavior in controlled environmental conditions or selective pressures. (AU) | |
| FAPESP's process: | 98/14247-6 - Center for Research on Cell-Based Therapy |
| Grantee: | Marco Antonio Zago |
| Support Opportunities: | Research Grants - Research, Innovation and Dissemination Centers - RIDC |